TNDM, US8753722037

Barclays keeps Tandem Diabetes Care stock at Hold with USD 18.00 target

Published on 10/08/2026 at 12:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 sales rose 5.77 percent to USD 254.56 million. Tandem Diabetes Care stock was EUR 14.10 on October 8, 2026, versus EUR 14.20.

TNDM, US8753722037, Illustration mit AI erstellt.

Tandem Diabetes Care (ISIN US8753722037) was trading at EUR 14.10 at Lang & Schwarz on October 8, 2026, at 12:11 p.m. CEST, down 0.70 percent versus the EUR 14.20 prior close. On October 7, 2026, Barclays maintained a Hold rating and a USD 18.00 price target, as Markets Insider reported.

Target stays at USD 18.00

The Barclays note gave Tandem a fresh analyst reference point while leaving the rating at Hold. The USD 18.00 target is separate from the euro quotation and cannot be used to calculate an upside percentage against the Lang & Schwarz price.

For the quarter ended June 30, 2026, revenue reached USD 254.56 million, up 5.77 percent from USD 240.68 million a year earlier, while GAAP net loss narrowed to USD 21.17 million from USD 52.40 million, according to Markets Insider.

Revenue growth meets execution risks

Tandem's second-quarter performance also included a 57.00 percent gross margin and worldwide pump shipments of 33,000, according to the company's earnings-call transcript published by Yahoo Finance. Management reaffirmed 2026 worldwide sales guidance of USD 1.065 billion to USD 1.085 billion and adjusted EBITDA margin guidance of 5.00 percent to 6.00 percent.

The same transcript identified infusion-set supply constraints as a factor affecting the quarter, while pharmacy adoption was becoming a larger part of the commercial model. That combination matters because the company is trying to expand recurring supply revenue while absorbing the near-term revenue effect of pharmacy pump shipments.

Results date set for November 5

Tandem plans to release third-quarter 2026 results after the market close on November 5, 2026, and to hold its earnings call at 4:30 p.m. ET, according to Business Wire. The Nasdaq quotation had a 52-week range of USD 12.26 to USD 29.65 as of October 7, 2026, while market capitalization was USD 1.1 billion as of October 8, 2026.

Stock remains below its prior close

Tandem Diabetes Care was trading at EUR 14.10 at Lang & Schwarz on October 8, 2026, at 12:11 p.m. CEST, down 0.70 percent versus the EUR 14.20 prior close at Lang & Schwarz on October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Tandem Diabetes Care stock.